@article{bbf1e5fe721f487a9d16eb984aad18d5,
title = "Machine Learning to Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia",
abstract = "Methicillin-resistant Staphylococcus aureus (MRSA) is an uncommon but serious cause of community-acquired pneumonia (CAP). A lack of validated MRSA CAP risk factors can result in overuse of empirical broad-spectrum antibiotics. We sought to develop robust models predicting the risk of MRSA CAP using machine learning using a population-based sample of hospitalized patients with CAP admitted to either a tertiary academic center or a community teaching hospital. Data were evaluated using a machine learning approach. Cases were CAP patients with MRSA isolated from blood or respiratory cultures within 72 h of admission; controls did not have MRSA CAP. The Classification Tree Analysis algorithm was used for model development. Model predictions were evaluated in sensitivity analyses. A total of 21 of 1,823 patients (1.2%) developed MRSA within 72 h of admission. MRSA risk was higher among patients admitted to the intensive care unit (ICU) in the first 24 h who required mechanical ventilation than among ICU patients who did not require ventilatory support (odds ratio [OR], 8.3; 95% confidence interval [CI], 2.4 to 32). MRSA risk was lower among patients admitted to ward units than among those admitted to the ICU (OR, 0.21; 95% CI, 0.07 to 0.56) and lower among ICU patients without a history of antibiotic use in the last 90 days than among ICU patients with antibiotic use in the last 90 days (OR, 0.03; 95% CI, 0.002 to 0.59). The final machine learning model was highly accurate (receiver operating characteristic [ROC] area = 0.775) in training and jackknife validity analyses. We identified a relatively simple machine learning model that predicted MRSA risk in hospitalized patients with CAP within 72 h postadmission.",
keywords = "MRSA infection, antibiotic stewardship, community-acquired pneumonia, machine learning, predictive model",
author = "Rhodes, {Nathaniel J.} and Roxane Rohani and Yarnold, {Paul R.} and Pawlowski, {Anna E.} and Michael Malczynski and Chao Qi and Sutton, {Sarah H.} and Zembower, {Teresa R.} and Wunderink, {Richard G.}",
note = "Funding Information: This study was supported by a New Investigator Award from the American Association of Colleges of Pharmacy to N. J. Rhodes. C. Qi, A. E. Pawlowski, and R. G. Wunderink were supported by the National Institutes of Health, grant number U19AI135964. The Electronic Data Warehouse is supported by the Northwestern University Clinical and Translational Science (NUCATS) Institute. Research reported in this publication was supported, in part, by the National Institutes of Health{\textquoteright}s National Center for Advancing Translational Sciences, grant number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The sponsor played no role in the study. N. J. Rhodes had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Author contributions were as follows: concept and design, N. J. Rhodes, S. H. Sutton, T. R. Zembower, R. G. Wunderink; acquisition, analysis, or interpretation of data, N. J. Rhodes, R. Rohani, P. R. Yarnold, A. E. Pawlowski, M. Malczynski, C. Qi, S. H. Sutton, T. R. Zembower, R. G. Wunderink; drafting of the manuscript, N. J. Rhodes, P. R. Yarnold; critical revision of the manuscript for important intellectual content, N. J. Rhodes, R. Rohani, P. R. Yarnold, A. E. Pawlowski, M. Malczynski, C. Qi, S. H. Sutton, T. R. Zembower, R. G. Wunderink; statistical analysis, N. J. Rhodes, P. R. Yarnold; obtained funding, N. J. Rhodes; administrative, technical, or material support, R. Rohani, A. E. Pawlowski, M. Malczynski, C. Qi; supervision, R. G. Wunderink. N. J. Rhodes reported receiving grants from Paratek and consulting fees from Third Pole Therapeutics during the conduct of the study. R. Rohani reports receiving grants from Midwestern University during the conduct of the study. C. Qi reports receiving grants from the National Institutes of Health during the conduct of the study. A. E. Pawlowski reports receiving grants from the National Institutes of Health during the conduct of the study. R. G. Wunderink reports receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported. Funding Information: This study was supported by a New Investigator Award from the American Association of Colleges of Pharmacy to N. J. Rhodes. C. Qi, A. E. Pawlowski, and R. G. Wunderink were supported by the National Institutes of Health, grant number U19AI135964. The Electronic Data Warehouse is supported by the Northwestern University Clinical and Translational Science (NUCATS) Institute. Research reported in this publication was supported, in part, by the National Institutes of Health{\textquoteright}s National Center for Advancing Translational Sciences, grant number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The sponsor played no role in the study. Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology. All Rights Reserved.",
year = "2023",
month = jan,
doi = "10.1128/aac.01023-22",
language = "English (US)",
volume = "67",
journal = "Antimicrobial agents and chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",
}